Last update: Aug. 7, 2019
Minimal risk for breastfeeding and infant.
Selective agonist for the vascular receptor of 5-hydroxytryptamine-1 (5-HT1, serotonin) with vasoconstrictor action at the intracranial level.
Indicated in acute migraine attack. Subcutaneous, oral or intranasal administration in a daily dose.
It is excreted in breastmilk in clinically insignificant amounts (Wojnar 1996).
Its very low oral bioavailability impedes its transfer breastmilk to infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
Several medical assocoations, experts and expert consensus consider its use to be safe during breastfeeding (Hale 2019, Briggs 2017, Bordini 2016, Becker 2015, Amundsen 2015, Davanzo 2014, Worthington 2013, Hutchinson 2013, Duong 2010, Cassina 2010, Jürgens 2009, Marcus 2008, Raña 2008, MacGregor 2007, Loder 2007).
American Academy of Pediatrics: this medication is usually compatible with breastfeeding (AAP 2001).
We do not have alternatives for スマトリプタン since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM